Rapid CNS delivery Leverage Zosano’s proprietary transdermal system that enables rapid onset of action for CNS therapeutics, presenting a pathway to expand reach for existing drugs with fast relief profiles to patients seeking quick symptom relief.

Existing drug repurposing Opportunity to partner on reformulation of established drugs with known safety and efficacy using the transdermal delivery platform, potentially accelerating regulatory timelines and market adoption in CNS indications.

Large unmet needs Target patient populations requiring fast-acting treatments and improved ease of use, where transdermal delivery can offer advantages over oral or injectable alternatives, aligning with payer and patient preference trends.

Technical differentiator Position the platform’s room-temperature stability and user-friendly administration as differentiators in near-term commercialization plans, enabling easier supply chain logistics and broader patient accessibility.

Strategic partnerships Engage with potential buyers or co-development partners in CNS space to explore asset monetization via licensing or asset sale, given the company’s asset portfolio and the recent history of asset transfers.